NOVATO, Calif., May 1, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 14, 2014 at 5:00 p.m. PDT/8:00 p.m. EDT. Julie Anne Smith, SVP and COO at Raptor, will present an update on the PROCYSBI commercial rollout and program updates. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
About Raptor Pharmaceutical
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic fatty liver disease, Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.
CONTACT: Georgia Erbez Chief Financial Officer Raptor Pharmaceutical Corp. (415) 408-6231 firstname.lastname@example.org INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 email@example.com MEDIA CONTACT: Carolyn Hawley Canale Communications (619) 849-5375 firstname.lastname@example.org
Source:Raptor Pharmaceutical Corp.